Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Целесообразность продолжения терапии бевацизумабом после прогрессирования у больных метастатическим колоректальным раком
Целесообразность продолжения терапии бевацизумабом после прогрессирования у больных метастатическим колоректальным раком
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Целесообразность сохранения введений бевацизумаба после первого прогрессирования метастатического колоректального рака до последнего времени оставалась спорным вопросом и, как правило, не применялась в клинической практике. Представлены результаты крупных международных исследований, свидетельствующие о нерациональности отмены бевацизумаба как компонента 2-й линии химиотерапии.
Ключевые слова: колоректальный рак, бевацизумаб, прогрессирование болезни.
Key words: colorectal cancer, bevacizumab, disease progression.
Ключевые слова: колоректальный рак, бевацизумаб, прогрессирование болезни.
________________________________________________
Key words: colorectal cancer, bevacizumab, disease progression.
Полный текст
Список литературы
1. Miles D, Harbeck N, Escudier B et al. Disease Course Patterns After Discontinuation of Bevacizumab: Pooled Analysis of Randomized Phase III Trials. J Clin Oncol 2011; 29 (1): 83.
2. Leonard B. Zaltz, Stephen Clarke et al. Bevacizumab in combination with Oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III studies. J Clin Oncol 2008; 26 (12).
3. Kozloff M, Ulcickas Yood M et al. Clinical Outcomes Associated with Bevacizumab- Containing Treatment of Metastatic Colorectal Cancer: The BRITE Observation Cohort Study. Oncologist 2009; 14: 862–70.
4. Grothey A, Sugrue MM, Purdie DM et al. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: Results from a large observational cohort study (BRiTE). J Clin Oncol 2008; 26: 5326–34.
5. Bendell JC, Bekaii-Saab TS, Cohn AL et al. Treatment Patterns and Clinical Outcomes in Patients with Metastatic Colorectal Cancer Initially Treated with FOLFOX-Bevacizumab or FOLFIRI-Bevacizumab: Results From ARIES, Bevacizumab Observational Cohort Study. Oncologist 2012. Sep 26. [Epub ahead of print].
6. Cohn AL, Bekaii-Saab T, Bendell JC et al. Clinical outcomes in bevacizumab (BV)-treated patients (pts) with metastatic colorectal cancer (mCRC): Results from ARIES observational cohort study (OCS) and confirmation of BRiTE data on BV beyond progression (BBP). Abstr. 3596.
7. Masi G, Loupakis F, Salvatore L et al. A randomized study evaluating the continuation of bevacizumab beyond progression in metastatic colorectal cancer patients who received bevacizumab as part of first-line treatment: results of the BEBYP trial by the Gruppo Oncologico Nord Ovest (GONO). Vienna 2012 Congress, Vienna 2012 App.
8. Bennouna J, Sastre J, Arnold D et al. Continuation of bevacizumab after fi rst progression in metastatic colorectal cancer (ML18147): a randomized phase 3 trial. Published Online November 16, 2012. http://dx.doi.org/10.1016/S1470-2045(12)70477-1
2. Leonard B. Zaltz, Stephen Clarke et al. Bevacizumab in combination with Oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III studies. J Clin Oncol 2008; 26 (12).
3. Kozloff M, Ulcickas Yood M et al. Clinical Outcomes Associated with Bevacizumab- Containing Treatment of Metastatic Colorectal Cancer: The BRITE Observation Cohort Study. Oncologist 2009; 14: 862–70.
4. Grothey A, Sugrue MM, Purdie DM et al. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: Results from a large observational cohort study (BRiTE). J Clin Oncol 2008; 26: 5326–34.
5. Bendell JC, Bekaii-Saab TS, Cohn AL et al. Treatment Patterns and Clinical Outcomes in Patients with Metastatic Colorectal Cancer Initially Treated with FOLFOX-Bevacizumab or FOLFIRI-Bevacizumab: Results From ARIES, Bevacizumab Observational Cohort Study. Oncologist 2012. Sep 26. [Epub ahead of print].
6. Cohn AL, Bekaii-Saab T, Bendell JC et al. Clinical outcomes in bevacizumab (BV)-treated patients (pts) with metastatic colorectal cancer (mCRC): Results from ARIES observational cohort study (OCS) and confirmation of BRiTE data on BV beyond progression (BBP). Abstr. 3596.
7. Masi G, Loupakis F, Salvatore L et al. A randomized study evaluating the continuation of bevacizumab beyond progression in metastatic colorectal cancer patients who received bevacizumab as part of first-line treatment: results of the BEBYP trial by the Gruppo Oncologico Nord Ovest (GONO). Vienna 2012 Congress, Vienna 2012 App.
8. Bennouna J, Sastre J, Arnold D et al. Continuation of bevacizumab after fi rst progression in metastatic colorectal cancer (ML18147): a randomized phase 3 trial. Published Online November 16, 2012. http://dx.doi.org/10.1016/S1470-2045(12)70477-1
Авторы
Н.В.Доброва, С.Л.Гуторов, Е.В.Черноглазова
Отделение химиотерапии и комбинированного лечения злокачественных опухолей ФГБУ РОНЦ им. Н.Н.Блохина РАМН
Отделение химиотерапии и комбинированного лечения злокачественных опухолей ФГБУ РОНЦ им. Н.Н.Блохина РАМН
________________________________________________
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.